From Wikipedia, the free encyclopedia
Content deleted Content added
| Line 1: | Line 1: | ||
|
{{Short description|American businessman}} |
{{Short description|American businessman}} |
||
|
[[File:David A. Ricks 2025.jpg |thumb|Ricks in Virginia in 2025]] |
[[File:David A. Ricks 2025.jpg |thumb|Ricks in Virginia in 2025]] |
||
|
”’David A. Ricks”’ (born |
”’David A. Ricks”’ (born <ref name=”Barrons”>https://www.barrons.com/articles/eli-lilly-dave-ricks-top-ceo-stock-price-bd7f1261</ref>) is an American businessman. He is currently the [[chair (officer)|chair]] and [[chief executive officer]] of pharmaceutical company [[Eli Lilly and Company]], assuming both roles in 2017.<ref>{{cite news |url=https://www.nytimes.com/2024/12/04/business/dealbook/eli-lilly-fda-rfk-jr.html |title=Eli Lilly Chief Says He Will Fight for the F.D.A., Challenging Kennedy’s Stance |work=The New York Times}}</ref><ref name=”elililly”>{{cite web |url=https://www.lilly.com/leadership/executive-committee/david-ricks |title=David A. Ricks |work=Eli Lilly and Company}}</ref> He is also a member of the board of directors of [[Adobe Inc.|Adobe]]<ref name=”elililly” /> and the [[Purdue University]] Board of Trustees.<ref>{{cite web |url=https://www.purdue.edu/bot/about/trustees/trustee-bios/ricks.php |title=David A. Ricks |work=Purdue University}}</ref> |
||
|
==Early life and background== |
==Early life and background== |
||
Revision as of 18:36, 15 November 2025
American businessman
David A. Ricks (born 1967[1][2]) is an American businessman. He is currently the chair and chief executive officer of pharmaceutical company Eli Lilly and Company, assuming both roles in 2017.[3][4] He is also a member of the board of directors of Adobe[4] and the Purdue University Board of Trustees.[5]
Early life and background
Ricks graduated from Purdue University in 1990 with a Bachelor in Science, as well as earning a Master of Business Administration in 1996 from Indiana University.[6]
Career
As CEO and chair of Eli Lilly and Company, Ricks has a salary package of $29.2 million a year as of 2024.[7]
After Donald Trump announced planned tariffs on pharmaceutical companies, Ricks stated that he was “not so sure” that tariffs were needed and instead supported permanent lower tax rates in the United States, including 15% for business production, and an extension of the Tax Cuts and Jobs Act, a law that Trump signed during his first term.[8][9]
